Search clinical trials for: c-Met, c-Met overexpression

Total 154 results

AbbVie

Active, not recruiting

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Australia, Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland and more
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-700 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Pravin T.P Kaumaya

Not yet recruiting

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoma | EGFR Overexpression

United States
Avistone Biotechnology Co., Ltd.

Recruiting

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Non-Small-Cell Lung Cancer

China
Enliven Therapeutics

Recruiting

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Colorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid Tumors

United States
Shanghai Henlius Biotech

Not yet recruiting

A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects

EGFR Overexpression
Henan Cancer Hospital

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Gastric Cancer

China
Fudan University

Not yet recruiting

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer | HER-2 Protein Overexpression
Centre Hospitalier Universitaire de Nīmes
Institut du Cancer de Montpellier - Val d'Aurelle

Not yet recruiting

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer (EPIcol)

Cancer of Cervix | Apoptosis
AbbVie

Not yet recruiting

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Non-Small Cell Lung Cancer
AbbVie

Recruiting

A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer (METRIX)

Non Small Cell Lung Cancer

Canada, United Kingdom
Changhai Hospital

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Seagen Inc.
Merck Sharp & Dohme LLC; RemeGen Co., Ltd.

Recruiting

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Urothelial Carcinoma

United States, Canada, Australia, Singapore
Seagen Inc.

Recruiting

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Urothelial Carcinoma

United States, France
QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Non-small Cell Lung Cancer

China
Chinese PLA General Hospital
Zhejiang University

Recruiting

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Lymphoma | Solid Tumor, Adult | EphA2 Overexpression | TP53 R273H | TP53 R175H | TP53 R248Q | TP53 R249S

China
Chinese PLA General Hospital
Zhejiang University

Recruiting

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Solid Tumor, Adult | KRAS G12D | EphA2 Overexpression | KRAS G12V | KRAS G12C

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Gastric Cancer
Orum Therapeutics USA, Inc.

Recruiting

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

United States
Omega Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I)

Hepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-Resectable

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Brown University
AstraZeneca

Recruiting

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Esophageal Cancer | Esophageal Adenocarcinoma | HER-2 Protein Overexpression | Gastroesophageal-junction Cancer

United States
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Italy, Finland and more
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (FORTITUDE-103)

Gastric Cancer | Gastroesophageal Junction Cancer

Korea, Republic of, Taiwan, Japan, Singapore, United States
ORIC Pharmaceuticals

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Solid Tumors

Korea, Republic of, United States, Australia, Taiwan, Poland, Canada, Hong Kong, United Kingdom
Morten Mau-Sørensen
Odense University Hospital; Aarhus University Hospital; Aalborg University Hospital

Recruiting

Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients (HERES)

Esophageal Squamous Cell Carcinoma | HER-2 Gene Amplification | HER-2 Protein Overexpression

Denmark
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Advanced Melanoma | Melanoma, Stage II | HER2-positive

China
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Israel, Italy, Spain, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, China, Belgium, Poland, Thailand, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
Baylor College of Medicine
National Cancer Institute (NCI); Stand Up To Cancer; Center for Cell and Gene... and other collaborators

Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Sarcoma | Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma | HER-2 Protein Overexpression | Undifferentiated Sarcoma

United States
Chinese PLA General Hospital

Recruiting

TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors

Solid Tumor, Adult | EGFR Overexpression

China
AbbVie

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Argentina, Brazil, Bulgaria, Chile, Czechia, Greece, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, Australia, France, Belgium, China, Austria, United Kingdom, Germany, South Africa, Mexi... and more
Centre Leon Berard

Recruiting

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) (TRacKING)

Cancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditions

France, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
Peking University

Not yet recruiting

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Esophageal Squamous Cell Carcinoma

China
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma

United States, Canada, United Kingdom, Japan, Australia, Argentina, Chile, Israel
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

Solid Tumor

China
Sunshine Lake Pharma Co., Ltd.

Recruiting

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Esophageal Cancer

China
Prince of Songkla University

Recruiting

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Glaucoma, Neovascular | Vascular Endothelial Growth Factor Overexpression

Thailand
VM Oncology, LLC

Recruiting

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Sarcoma | Cervical Cancer | Breast Cancer | Adenoid Cystic Carcinoma | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Thymic Carcinoma | Lung Cancer | Mesothelioma | Bladder Cancer | Head and Neck Carcinoma | Uterine Cancer | Any Solid Tumors Progressed After a Prior Immunotherapy

United States, Puerto Rico
Grupo Espanol de Investigacion en Sarcomas

Recruiting

Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc)

Osteosarcoma | Chordoma | Soft-tissue Sarcoma

Spain
Northwell Health

Recruiting

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

Glioblastoma | Brain Cancer | Brain Tumor | GBM | Brain Neoplasm | Brain Neoplasm, Malignant | EGFR Gene Overexpression

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

Breast Cancer

United States
Amgen

Active, not recruiting

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (FORTITUDE-201)

Squamous-Cell Non-Small-Cell Lung Cancer

France, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland
University of California, Irvine
Applied Biology, Inc.

Withdrawn

COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression

Covid19 | Androgen Receptor Gene Overexpression

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | CD20 Positive | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | CCND1 Protein Overexpression | CD5 Positive | FCER2 Negative | Pleomorphic Variant Mantle Cell Lymphoma | t(11;14)(q13;q32)

United States
AbbVie

Active, not recruiting

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Australia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Taiwan

Search clinical trials for: c-Met, c-Met overexpression

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations